Tag Archives: XRAY

Somewhat Favorable Press Coverage Somewhat Unlikely to Affect Dentsply Sirona (XRAY) Share Price

Headlines about Dentsply Sirona (NASDAQ:XRAY) have been trending somewhat positive this week, Accern reports. Accern ranks the sentiment of news coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Dentsply Sirona earned a media sentiment score of 0.20 on Accern’s scale. Accern also assigned news coverage about the medical instruments supplier an impact score of 48.0193831926448 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

Here are some of the news articles that may have impacted Accern’s rankings:

Get Dentsply Sirona alerts:

Brokerages Expect Dentsply Sirona (XRAY) Will Announce Earnings of $0.60 Per Share (americanbankingnews.com) Insider Selling: Dentsply Sirona (XRAY) Director Sells 414 Shares of Stock (americanbankingnews.com) Dentsply Sirona (XRAY) to Post Q2 2018 Earnings of $0.58 Per Share, Barrington Research Forecasts (americanbankingnews.com) Active Healthcare Stock’s Momentum: DENTSPLY SIRONA Inc. (XRAY) (nasdaqplace.com) Electric Dental Handpieces Market Global Players 2018: Kavo, Dentsply Sirona, Bien Air, W&H and NSK (theexpertconsulting.com)

Shares of Dentsply Sirona traded up $0.39, hitting $46.93, during trading hours on Friday, according to Marketbeat Ratings. 2,472,971 shares of the stock were exchanged, compared to its average volume of 2,453,026. The company has a current ratio of 2.23, a quick ratio of 1.45 and a debt-to-equity ratio of 0.25. The company has a market cap of $10.14 billion, a P/E ratio of 17.64, a P/E/G ratio of 2.07 and a beta of 1.26. Dentsply Sirona has a one year low of $44.21 and a one year high of $68.98.

Dentsply Sirona (NASDAQ:XRAY) last posted its quarterly earnings data on Sunday, May 6th. The medical instruments supplier reported $0.45 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.42 by $0.03. The business had revenue of $956.10 million during the quarter, compared to the consensus estimate of $942.20 million. Dentsply Sirona had a negative net margin of 38.32% and a positive return on equity of 8.63%. Dentsply Sirona’s quarterly revenue was up 6.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.49 EPS. equities research analysts forecast that Dentsply Sirona will post 2.58 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Friday, July 13th. Investors of record on Friday, June 29th will be paid a dividend of $0.0875 per share. This represents a $0.35 annualized dividend and a yield of 0.75%. The ex-dividend date is Thursday, June 28th. Dentsply Sirona’s payout ratio is currently 13.16%.

Several analysts have commented on the stock. Zacks Investment Research downgraded shares of Dentsply Sirona from a “hold” rating to a “sell” rating in a research report on Friday. ValuEngine downgraded shares of Dentsply Sirona from a “sell” rating to a “strong sell” rating in a research report on Tuesday, May 8th. Robert W. Baird decreased their target price on shares of Dentsply Sirona to $71.00 and set an “outperform” rating for the company in a research report on Tuesday, May 8th. Barrington Research decreased their target price on shares of Dentsply Sirona from $70.00 to $54.00 and set an “outperform” rating for the company in a research report on Tuesday, May 8th. Finally, Barclays reissued a “hold” rating and issued a $55.00 target price on shares of Dentsply Sirona in a research report on Tuesday, May 8th. Four investment analysts have rated the stock with a sell rating, four have given a hold rating and nine have issued a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $64.64.

In related news, CFO Nicholas W. Alexos bought 50,000 shares of the business’s stock in a transaction that occurred on Wednesday, May 9th. The stock was purchased at an average cost of $44.71 per share, for a total transaction of $2,235,500.00. Following the purchase, the chief financial officer now directly owns 25,411 shares in the company, valued at $1,136,125.81. The purchase was disclosed in a filing with the SEC, which is available through this link. Also, CEO Donald M. Jr. Casey bought 22,500 shares of the business’s stock in a transaction that occurred on Wednesday, May 9th. The shares were bought at an average price of $44.52 per share, with a total value of $1,001,700.00. Following the completion of the purchase, the chief executive officer now owns 92,408 shares in the company, valued at $4,114,004.16. The disclosure for this purchase can be found here. 1.93% of the stock is owned by corporate insiders.

About Dentsply Sirona

DENTSPLY SIRONA Inc designs, develops, manufactures, and markets various dental and oral health products, and other consumable healthcare products primarily for the professional dental market worldwide. The company operates in two segments, Technologies & Equipment; and Consumables. Its dental supplies include endodontic instruments and materials, dental anesthetics, prophylaxis pastes, dental sealants, impression materials, restorative materials, tooth whiteners, and topical fluoride products; and small equipment products comprise dental hand pieces, intraoral curing light systems, dental diagnostic systems, and ultrasonic scalers and polishers.

Insider Buying and Selling by Quarter for Dentsply Sirona (NASDAQ:XRAY)